PT  - JOURNAL ARTICLE
AU  - Cheon Tae Kim
AU  - Tae-Ok Kim
AU  - Hong-Joon Shin
AU  - Young Chun Ko
AU  - Yeong Hun Choe
AU  - Hak-Ryul Kim
AU  - Yong-Soo Kwon
TI  - Bedaquiline and Delamanid for the Treatment of Multidrug-resistant Tuberculosis: A Multi-center Cohort Study in Korea
AID  - 10.1183/13993003.02467-2017
DP  - 2018 Jan 01
TA  - European Respiratory Journal
PG  - 1702467
4099  - http://erj.ersjournals.com/content/early/2018/02/08/13993003.02467-2017.short
4100  - http://erj.ersjournals.com/content/early/2018/02/08/13993003.02467-2017.full
AB  - Relatively little is known about the efficacy and safety of the programmatic use of bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This study evaluated 61 patients with MDR-TB treated with bedaquiline (n=39), delamanid (n=11), or both, either sequentially (n=10) or in co-administration (n=1), for more than 1 month, combined with a World Health Organization-recommended regimen. Of these, 49 (80.3%) were men and 12 (19.7%) were women. The median age was 53 years (interquartile range [IQR]=38.5–61.0 years). Forty-two (68.9%) patients had fluoroquinolone-resistant MDR-TB and 16 (26.2%) had extensively drug-resistant TB. The median duration of treatment with bedaquiline and/or delamanid was 168 days (IQR 166.5–196.5 days), with 33 (54.1%) receiving linezolid for median 673 days (IQR 171–736 days). Of the 55 patients with positive sputum cultures at the start of bedaquiline and/or delamanid treatment, 39 (70.9%) achieved sputum culture conversion within a median of 119 days. Treatment was halted in four patients (6.6%) because of prolonged corrected QT interval. In conclusion, bedaquiline and delamanid were effective and safe for treating MDR-TB, with initial evidence of sequential administration of these two drugs as a viable treatment strategy for patients when an adequate treatment regimen cannot be constructed.Bedaquiline and delamanid were effective and safe for MDR-TB treatment when combined with WHO-recommended regimensFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Shin has nothing to disclose.Conflict of interest: Dr. Kim has nothing to disclose.Conflict of interest: Dr. Kim has nothing to disclose.Conflict of interest: Dr. Ko has nothing to disclose.Conflict of interest: Dr. Choe has nothing to disclose.Conflict of interest: Dr. Kwon reports grants from National Research Foundation of Korea , during the conduct of the study.